• SL Science posted a net loss of USD 3.82 million, widening 221% from a year earlier.
• Net revenue fell 35% to USD 2.2 million as Taiwan exosome operations shifted from retail sales toward a wholesale distributor model.
• Operating loss widened to USD 3.84 million as total operating expenses rose 47% to USD 4.61 million.
• Cash, cash equivalents and restricted cash totaled USD 1.26 million at Dec. 31, 2025, down from USD 4.14 million a year earlier.
• Closed its Nasdaq listing and business combination on June 12, 2026, alongside a USD 7.8 million PIPE; targets a CD-19 Armed-T IND in Q1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SL Science Holding Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606181713PRIMZONEFULLFEED9749544) on June 18, 2026, and is solely responsible for the information contained therein.